23948sdkhjf
Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Antigens and Antibodies for 2024-2025 Influenza Vaccine Strains Are Available Now!

On February 23rd, 2024, the World Health Organization (WHO) announced the recommendations for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season. To support vaccine research, Sino Biological has released the recombinant antigens for 2024-2025 influenza vaccine strains. 

With the world’s largest viral antigen collection, ProVir®, Sino Biological provides a range of recombinant influenza antigen products, including Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains in recent years. A large collection of monoclonal antibodies against the flu antigens are also available to support the development of relevant assays and diagnostic kits.

Learn more about our recombinant antigens for 2024-2025 Influenza Vaccine Strains!

Building Expertise in Influenza Antigen and Antibody Development for Over 15 Years:

Pan Influenza A and B Antibodies

Influenza Vaccine Development and Production Solutions

600+ Influenza Virus Antigen Bank

Customized Viral Protein Production and Antibody Development through CRO

Sino Biological Europe GmbH
Düsseldorfer Str. 40
65760 Eschborn
Tyskland
VAT nummer: DE323950120

Kontaktperson

SBEG
Sino Biological Europe GmbH
order_eu@sinobiologicaleu.com

Sänd till en kollega

0.039